NorthWest Biotherapeutics Inc (NWBO)

[ccie1024]

ae kusterer Tuesday, 02/08/22 09:31:49 AM
Re: None 0
Post # of 442159

flipper44 Member Level Tuesday, 02/08/22 05:05:55 AM
Re: flipper44 post# 441875 0
Post #
442097
of 442156
Four days ago: Italian meta-analysis of 15 small trials.

Published February 4, 2022

Quote:
In contrast, DCV (dendritic cell vaccination) led to significantly longer 1-year OS (HR = 1.936, 95% CI: 1.396–2.85, p = 0.001) and longer 2-year OS (HR = 3.670, 95% CI: 2.291–5.879, p = 0.001) versus control groups. Hence, introducing DCV could lead to increased 1 and 2-year survival of patients by 1.9 and 3.6 times, respectively. Conclusion: Antitumor regimens including DCV can effectively improve mid- term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in (certain) patients affected by a very poor prognosis. https://mdpi-res.com/d_attachment/curroncol/curroncol-29-00075/article_deploy/curroncol-29-00075.pdf

Quote:
It should be noted that, as shown in Table 1, many studies integrated into this meta-analysis are of a non-randomized or historical type. This may reduce the statistical significance of the analysis.